Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

4597.T

STRONG SELLREMOVE

Solasia Pharma K.K. · Healthcare · Japan · $55M · Avg Vol: $10M/d

11
StockRank
Q
30
V
35
M
31
P/E (TTM)
—
ROE
-69.5%
D/E
0.1x
Dividend %
—
Director Trades · 180d
None in 180d →
Buybacks · 180d
None in 180d →
AI CONVICTION THESIS

A micro-cap Japanese oncology-focused specialty pharma company with a history of net losses and lack of commercial scale, failing our basic financial quality screens.

COMPANY DESCRIPTION

Solasia Pharma K.K. is a specialty pharmaceutical company that licenses, develops, and commercializes innovative oncology drugs and supportive care products for the Asian market. The company operates an asset-light business model, sourcing promising clinical-stage candidates globally and managing their clinical development and regulatory approval in Japan and China. Its competitive moat is its specialized regulatory expertise and established commercialization network in the Asian oncology sector.

FINANCIAL SUMMARY (USD)

Year20212022202320242025CAGR
Revenue—7M4M2M3M-26.8%
EPS-0.12-0.10-0.04-0.06——
Shares—168M174M218M264M+56.6%
Debt—231,318375,11075,022100,029-24.4%
Equity—17M12M6M10M-15.3%
Op CF—-15M-13M-2M-6M—
Inv CF—-1M-3M00—
Fin CF—2M16M2M7M—
Loading...
PRICE (1M)-21.9%
0.130.150.170.190.21May 8May 29Jun 18
SMA 50SMA 200
Close
$0.16
RSI (14)
45.5
52W High
$0.30
From 52W High
0.5%

SCORE BREAKDOWN

Quality
30
ROIC
-51.8%13.3
ROE
-69.5%12.0
GP/Assets
9.8%25.5
Op. Margin
-5083.3%3.3
FCF/Assets
—N/A
Piotroski
—7.2
Int. Cover
-50.0x6.4
D/E Ratio
0.05x74.2
Current Ratio
8.02x82.8
Value
35
P/E (TTM)
—N/A
EV/EBITDA
-5.6x74.4
P/FCF
—N/A
P/B
3.8x31.5
P/S
16.0x19.5
Div Yield
—N/A
Momentum
31
52W High %
52%26.6
RS 6M
-60%18.3
SMA 50/200
0.92x40.5
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—50.6
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$55M
P/E (Forward)
-11.4x
Gross Margin
50.5%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 4597.T are excluded.

TickerCompanyMkt CapStockRankSignal
4597.TSolasia Pharma K.K.(you)$55M11STRONG SELL
2929.TPharma Foods International Co., Ltd.$114M30SELL
4512.TWakamoto Pharmaceutical Co.,Ltd.$61M45HOLD
4538.TFuso Pharmaceutical Industries,Ltd.$109M34SELL
4574.TTaiko Pharmaceutical Co.,Ltd.$81M83STRONG BUY
4569.TKYORIN Pharmaceutical Co., Ltd.$457M56HOLD
4595.TMizuho Medy Co.,Ltd.$207M81STRONG BUY
9273.TKoa Shoji Holdings Co.,Ltd.$210M84STRONG BUY
4887.TSawai Group Holdings Co., Ltd.$1.3B48HOLD
4577.TDaito Pharmaceutical Co.,Ltd.$218M85STRONG BUY

Peer medians: ROE 8.4% · P/E 15.5x · Gross margin 47.8%

Solasia Pharma K.K. (4597.T) — Stock Score Summary

Solasia Pharma K.K. (4597.T) has a MoatMap StockRank of 11/100 based on Quality (30/100), Value (35/100), and Momentum (31/100) factor scores. The current signal is STRONG SELL. A micro-cap Japanese oncology-focused specialty pharma company with a history of net losses and lack of commercial scale, failing our basic financial quality screens.

Solasia Pharma K.K. is a specialty pharmaceutical company that licenses, develops, and commercializes innovative oncology drugs and supportive care products for the Asian market. The company operates an asset-light business model, sourcing promising clinical-stage candidates globally and managing their clinical development and regulatory approval in Japan and China. Its competitive moat is its specialized regulatory expertise and established commercialization network in the Asian oncology sector.

Key Financial Metrics

Price$0.16
Market Cap$55M
P/E (Forward)-11.43
Price/Book3.77
Return on Equity-69.5%
Return on Invested Capital-51.8%
Debt/Equity5.04
Gross Margin50.5%
Operating Margin-5083.3%
Revenue Growth-76.0%

Solasia Pharma K.K. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (Japan).

Frequently Asked Questions

What is Solasia Pharma K.K.’s (4597.T) StockRank?
MoatMap’s StockRank for Solasia Pharma K.K. (4597.T) is 11/100, with a Strong Sell signal. It is a composite of Quality (30), Value (35), and Momentum (31) factor ranks across MoatMap’s 20,000+ stock universe.
Does Solasia Pharma K.K. have an economic moat?
Solasia Pharma K.K. (4597.T) has a Quality factor score of 30/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Solasia Pharma K.K. a buy, hold, or sell?
MoatMap’s current signal for Solasia Pharma K.K. (4597.T) is Strong Sell, based on a StockRank of 11/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Solasia Pharma K.K. in?
Solasia Pharma K.K. (4597.T) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (Japan).
Browse all ranked stocks4597.T deep dive reportAI ChampionsHow we score stocksSense-check another stock